A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)
clinical trial
Press Enter · cited answer in seconds
0 sources
A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)
Summary
A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) is a clinical trial[1].
Key Facts
- A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)'s instance of is recorded as clinical trial[2].
- A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)'s start time is recorded as +2020-04-12T00:00:00Z[3].
- A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)'s end time is recorded as +2021-01-31T00:00:00Z[4].
- A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)'s number of participants is recorded as {'unit': '1', 'amount': '+508'}[5].
- A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)'s title is recorded as A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years[6].
- A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)'s short name is recorded as CTII-nCoV[7].
- A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)'s minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[8].
- A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)'s ClinicalTrials.gov ID is recorded as NCT04341389[9].
- A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)'s clinical trial phase is recorded as phase II clinical trial[10].
- A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)'s study type is recorded as interventional study[11].